A brain signature highly predictive of future progression to Alzheimer's
  dementia by Dansereau, Christian et al.
A brain signature highly predictive of future
progression to Alzheimer’s dementia
Christian Dansereaua,b,∗, Angela Tamc, AmanPreet Badhwara,
Sebastian Urchsc, Pierre Orbana,e,f, Pedro Rosa-Netod, Pierre Belleca,b,∗, for
the Alzheimer’s Disease Neuroimaging Initiative∗∗
aCentre de Recherche de l’Institut Universitaire de Ge´riatrie de Montre´al, Montre´al, CA
bDe´partement d’Informatique et de recherche ope´rationnelle, Universite´ de Montre´al,
Montre´al,CA
cIntegrated Program in Neuroscience, McGill University, Montre´al,CA
dDouglas Mental Health institute, McGill University, Montre´al,CA
eCentre de Recherche de l’Institut Universitaire en Sante´ Mentale de Montre´al, Montre´al,
CA
fDe´partement de Psychiatrie, Universite´ de Montre´al, Montre´al, CA
Abstract
Early prognosis of Alzheimer’s dementia is hard. Mild cognitive impairment
(MCI) typically precedes Alzheimer’s dementia, yet only a fraction of MCI in-
dividuals will progress to dementia, even when screened using biomarkers. We
propose here to identify a subset of individuals who share a common brain sig-
nature highly predictive of oncoming dementia. This signature was composed
of brain atrophy and functional dysconnectivity and discovered using a machine
learning model in patients suffering from dementia. The model recognized the
same brain signature in MCI individuals, 90% of which progressed to dementia
within three years. This result is a marked improvement on the state-of-the-
art in prognostic precision, while the brain signature still identified 47% of all
MCI progressors. We thus discovered a sizable MCI subpopulation which rep-
resents an excellent recruitment target for clinical trials at the prodromal stage
of Alzheimer’s disease.
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1. Introduction
Alzheimer’s disease (AD) is the most common age-related neurodegenerative
disorder. The typical progression of late-onset, sporadic AD comprises a lengthy
preclinical stage, a prodromal stage of mild cognitive impairment (MCI), and
a final stage of dementia. Usually, by the time patients suffer from dementia,
severe and irreversible neurodegeneration has already occurred. In order to be
effective, therapies should likely be initiated at earlier stages of the disease. For
this reason, many works have aimed at finding biomarkers that can predict fu-
ture progression to AD dementia at the prodromal or even preclinical stages
(Rathore et al., 2017; Orban et al., 2017). Accurate prediction of progression
from MCI to AD dementia has however proven to be challenging, likely due
to the considerable heterogeneity in brain pathology underlying both of these
conditions (Rathore et al., 2017). We propose here to work around the het-
erogeneity issue by identifying a subset of individuals with MCI who share a
homogeneous brain signature highly predictive of progression to AD dementia.
A clinical diagnosis of Alzheimer’s dementia is primarily established on the
basis of amnestic (e.g. memory) or nonamnestic (e.g. language, visual, exec-
utive) cognitive symptoms that interfere with the patient’s activities of daily
living. The diagnosis also requires the absence of evidence for concomitant neu-
rological diseases that can substantially affect cognition, such as Lewy body
dementia, fronto-temporal dementia or vascular dementia (McKhann et al.,
2011). MCI show a noticeable and measurable decline in cognitive abilities,
including memory and thinking skills, yet this decline is not severe enough to
qualify for dementia (Petersen et al., 2014). While MCI is considered an inter-
mediate stage between the expected cognitive decline of normal aging and the
more-serious decline of dementia, not all MCI patients progress to Alzheimer’s
dementia. Across 41 robust MCI cohort studies, an overall annual conversion
rate of 6.5% to Alzheimer’s dementia was reported (Mitchell 2009). A modest
conversion to dementia of 30-50% even in long-term (> 5 years) observational
studies, highlights the heterogeneity present in the MCI population.
Imaging biomarkers and machine learning algorithms are increasingly used to
complement neuropsychological testing for AD diagnosis and prognosis (Dubois
et al., 2007; Rathore et al., 2017). Established imaging biomarkers of AD are
Positron Emission Tomography (PET) glucose metabolism, beta-amyloid and
tau deposits (Fodero-Tavoletti et al., 2011; Sperling et al., 2011), as well as non-
invasive structural magnetic resonance imaging (sMRI) brain atrophy (Lerch
et al., 2005). Currently the state-of-the-art performance on the most popular
reference dataset, assembled by the Alzheimer’s disease neuroimaging initiative
(ADNI), reaches 95% accuracy to classify AD vs cognitively normal (CN) (Fan
et al., 2008b; Zhu et al., 2014; Xu et al., 2015; Zu et al., 2016), and 80% accuracy
to identify patients with MCI who will progress to AD dementia in the next
three years (Mathotaarachchi et al., 2017; Moradi et al., 2015; Eskildsen et al.,
2013; Wee et al., 2013; Gaser et al., 2013; Davatzikos et al., 2011; Koikkalainen
et al., 2011; Misra et al., 2009). Accuracy scores, however, are difficult to
interpret in isolation. Korolev et al. (2016) for example, separately reported the
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specificity (76%, proportion of stable MCI being correctly identified), sensitivity
(83%, proportion of progressor MCI being correctly identified), and precision
(80%, proportion of actual progressors amongst individuals identified as such).
Precision is, in other words, the rate of progression in the subpopulation of
MCI patients for which the machine learning algorithm makes a prognosis of
dementia. Precision is thus a key metric for enrichment in clinical trials, as
it dictates how many patients will decline in the absence of treatment. For a
given sensitivity and specificity, the precision depends on the baseline rate of
progression in the original MCI sample. The progression rate observed in the
sample used in this paper (ADNI2) is 34%, and corresponds with the range
typically observed in other cohorts followed for over 3 years (Mitchell et al.,
2009). Adjusted to a 34% baseline progression, the precision levels reported so
far in the literature ranged from 50% to 75%, see Table 1. There is, therefore,
substantial margin for improvements in terms of prognostic precision for AD
dementia within 3 years, which is the focus of this work.
The precision of imaging-based diagnosis of AD in past studies is likely lim-
ited by the pathophysiological heterogeneity of clinical diagnosis. The actual
cause of dementia, AD or otherwise, can currently only be confirmed by a post
mortem brain examination. The hallmarks of AD are the accumulation of beta-
amyloid plaques and tau protein neurofibrillary tangles in the brain, as well
as marked atrophy of the medial temporal lobe. The analysis of Beach et al.
(2012) revealed an important mismatch between clinical and histopathological
diagnoses: sensitivity ranged from 71% to 87%, and specificity ranged from 44%
to 71%, depending on the level of confidence in the clinical and pathophysiolog-
ical examination. In particular, 30% of patients diagnosed with AD dementia
in that study had no or minimal signs of AD pathology, while markers of AD
pathology has been observed in 10% to 30% of cognitively normal (CN) individ-
uals, as well as 40% of patients diagnosed with non-AD dementia (Beach et al.,
2012). In the MCI population Petersen et al. (2014) reported prevalence of 4.8%
per year. In addition to such incorrect diagnoses, co-occurrence of other age-
related neurodegenerative diseases is common, including vascular brain injury,
Lewy body disease, or hippocampal sclerosis Rabinovici et al. (2017); Jellinger
et al. (2014). Individuals suffering from MCI in particular exhibit a wide range
of brain pathologies (Stephan et al., 2012). In summary, the clinical diagnoses
currently used are often incorrect (wrong underlying disease) and incomplete
(missing several interacting diseases). Brain markers likely cannot be linked to
clinical diagnoses with high precision in this context.
In this work, we proposed a new machine learning model that worked around
the issue of heterogeneity by identifying a subgroup of patients who (1) shared
homogeneous brain abnormalities; and (2) had a highly predictable clinical diag-
nosis or prognosis. A cluster analysis was first used on structural and functional
magnetic resonance images to identify subtypes of brain atrophy and functional
connectivity in a sample mixing CN individuals with patients suffering from AD
dementia. Using a novel two-step procedure, a model was trained to identify
a brain signature mixing subtypes from different modalities, that was highly
specific of patients with dementia. We then identified a subset of MCI patients
3
presenting with this brain signature, and evaluated the rate of progression to
dementia within 3 years in these individuals.
2. Results
Simple simulation
Figure 1: Panel A show the identification of easy cases for each class, Panel B prediction of
clinical labels in a two-class problem, in the presence of heterogeneous labels in a subset of
the data. The first column shows the initial classification problem with the distribution of
the two classes. The second column shows a basic classifier decision hyperplane. The third
column shows the subjects that have been flagged as high hit probability in hard color and
the low hit probabilities with some transparency. The fourth column shows the final decision
hyperplane of the red subjects with the HPS signature.
We first illustrated the behaviour of the proposed method with a simple sim-
ulation (Figure 1A). The task was to classify two classes using a separation line:
blue dots for controls and red dots for patients. The distribution of both red
and blue subjects was heterogeneous, in the sense that each distribution was a
mixture of several Gaussian classes. Some of these classes were clearly separa-
ble, yet others were not, with blue and red points closely overlapping (maybe
because of incorrect or incomplete diagnosis). When a standard classifier was
applied on that data, it identified a separation line making a tradeoff in sensi-
tivity and specificity across all examples (see Figure 1B, second column). By
perturbing the data, it was possible to identify the “easy cases”, i.e. the data
point that can be reliably classified correctly: more opaque points are associated
with more reliable predictions and clearly identify the two well-separated classes
at the top in Figure 1B, third column. A separate model was then trained to
identify the“easy cases” red points (see Figure 1B, fourth columns). The re-
sulting prediction of red labels had limited sensitivity, as the problematic cases
were not being detected at all, but it had near perfect specificity and precision.
Multimodal imaging markers
We extracted multimodal (structural and functional) measures of brain or-
ganization that could be used for automated AD diagnosis. The measures were
derived from the baseline MRI scans of the ADNI2 cohort, which included
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anatomo-functional imaging for CN subjects (N=49) as well as patients suf-
fering from AD dementia (N=24) (available sample size post quality-control on
10/2016). We decided to include a range of different measures previously shown
to be sensitive markers of AD dementia. These included gray matter (GM)
thickness (Querbes et al., 2009; Eskildsen et al., 2013), GM volume of vari-
ous brain structures (Karas et al., 2004), as well as seed-based functional MRI
(fMRI) connectivity maps generated for 20 intrinsic connectivity brain networks
(Urchs et al., 2017).
Substantial inter-individual variations were observed in the distribution of
normalized brain imaging measures. For example, some subjects showed higher-
or lower-than average volumetric measures across extensive brain territories,
such as the right medial occipital cortex in subject 1 (lower) and subject 73
(higher), see Figure 2A. We investigated whether such patterns could be found
systematically in a subgroup of subjects. For this purpose, we quantified the
similarity of GM volume maps between all pair of subjects using a Pearson cor-
relation coefficient (Figure 2B). A cluster analysis revealed the presence of three
subgroups of subjects with homogeneous GM volume maps. These subgroups
were apparent as squares with high similarity values along the diagonal of the
inter-subject similarity matrix, Figure 2B. These squares outline the spatial
similarities of GM volume maps of subjects within a specific subgroup. By con-
trast, low similarity values were observed in elements outside of these squares,
which corresponded to pairs of subjects falling into different subgroups. A
subtype template was generated for each subgroup by averaging the maps of
individuals within that subgroup, Figure 2B). In particular, subtypes 2 and 3 of
GM volumetric maps reproduced the pattern observed in the occipital cortex of
subjects 1 and 73, respectively. The separation between clusters was not clear-
cut in matrix 2B, suggesting a continuum rather than discrete subtypes. We
thus extracted a continuous measure (Pearson’s correlation) of similarity, called
“subtype weights”, between each individual map and each subtype map, Figure
2D). The subtyping procedure outlined above was applied independently for
each type of measure (volumetric, cortical thickness, rs-fMRI) and each brain
network (for rs-fMRI). We confirmed by visual inspection the presence of at least
three subtypes for each modality/network, which we thus selected as a common
number of subtypes across all modalities/networks for subsequent analyses.
Prediction of AD
We established a baseline performance for automatic classification of CN
vs AD subjects using a well established machine learning model, i.e. a linear
support vector machine model (SVM) (Cortes and Vapnik, 1995). The model
reached 70% precision (specificity 86%, sensitivity 67%) using tenfold cross-
validation and multimodal (fMRI + sMRI) subtype weights, Figure 3. Training
only on fMRI subtypes or only on sMRI subtypes yielded lower performances:
38% precision (specificity 47% and sensitivity 67%) for fMRI alone and 67%
precision (specificity 84%, sensitivity 67%) for sMRI alone. Note that, dur-
ing cross-validation, the training of the model included both the generation of
subtypes and the optimization of the SVM parameters.
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Figure 2: Demeaned gray matter volume measures of the right hemisphere. Panel A shows
individual maps and the correlation of every subject with all other subjects in Panel B. Panel
C shows the subtypes templates representing subgroups in the dataset. Panel D shows the
association of each individual map in A with each subtype template in C.
Identifying easy cases
As we outlined in the introduction, the core idea of our approach was to
identify a subset of subjects for which clinical labels are easy to predict, such as
the points on the left in Figure 1A. To identify these “easy cases”, we randomly
perturbed the input data of the SVM model many times through subsampling,
and assessed the hit probability for any given subject to be properly classi-
fied. We found that 68% of individuals had a perfect (100%) hit probability,
with a small subset of subjects (18%) exhibiting less reliable predictions (hit-
probability < 90%), Supplementary material S1). We defined the “easy cases”
as the subgroup of individuals reaching perfect hit probability.
Predicting easy cases
The next step of the method was to train a logistic regression (Fan et al.,
2008a) to predict the AD “easy cases” Figure 6B, analogous to the rightmost
column of Figure 1B. The full multi-stage process of subtype extraction, hit
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Figure 3: Figure shows the precision, specificity and sensitivity of the three modalities (fMRI,
sMRI and fMRI+sMRI) at each stage (Base: basic classifier and HPS: highly predictive
signature). Significant differences are shown with ∗ for p < 0.05 and ∗∗ for p < 0.001).
probability estimation, and logistic regression was cross-validated using a ten-
fold scheme in order to generate the performance of the prediction of AD “easy
cases”. A perfect 100% precision (specificity 100%, sensitivity 36%) was reached
for AD “easy cases”, using multimodal structural and functional features. The
multimodal HPS performance was a significant improvement (in precision and
specificity, p < 0.001) compared to the model trained on fMRI only, precision
of 60% (specificity 96%, sensitivity 13%), and sMRI only, precision of 88%
(specificity 98%, sensitivity 29%), see Figure 3. Compared to the reference SVM
model, with multimodal features, the precision of our proposed HPS model was
improved by a wide margin (30%, p < 0.001), as well as the specificity (15%,
p < 0.001), at the cost of a marked loss in sensitivity (30%, p < 0.001). See
Supplementary material Table S2 for a list of the performance of each model.
Highly predictive brain signature
The logistic regression model used to predict AD “easy cases” is based on
a set of coefficients, which give more or less weight to a particular subtype and
modality. As such, the individuals flagged as AD “easy cases” can be seen as
sharing a brain HPS, composed of a combination of subtype maps. The lo-
gistic model may in theory ignore a subtype or a modality entirely, by setting
the corresponding weights to zero. In practice, we found that the HPS relied
on all three types of measures (functional connectivity, cortical thickness, and
gray matter volume), Figure 4A. To rank the contribution of each modality
in the decision process, we computed the absolute sum of the coefficients for
each measure, relative to the sum of all absolute coefficients (Figure 4B). The
thickness was the most important measure (60%), followed by the volumetric
measures (29%), and finally functional connectivity (11%). The highest con-
tributions came from four subtypes of thickness: bilateral patterns of cortical
atrophy in temporal, sagittal and frontal areas (one subtype per hemisphere),
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Figure 4: Panel A shows the contribution of each modality to the decision, the ratios are
computed by the sum of the absolute coefficient for each modality. Panel B shows the co-
efficients of the high-confidence prediction model for each subtype map. Panel C shows, on
top, the average maps for each modality and on the bottom the subtype maps used for the
high-confidence prediction.
and bilateral, opposite patterns of increased thickness (one subtype per hemi-
sphere), Figure 4C. Two lateralized volumetric subtypes showed gray matter
volume loss in the left motor, and right frontal areas as well as a gray volume
increase in the left frontal and limbic regions. Finally, one functional subtype
was very noisy and barely contributed to the model, while the other highlighted
a connectivity subtype connecting the visual network with frontal areas.
Prediction of progression to dementia
We applied the HPS model to patients with MCI from the ADNI2 cohort,
with the hypothesis that those with the signature would likely progress to AD
dementia. The imaging sample for this experiment included the baseline struc-
tural and functional scans of all MCI patients in the ADNI2 cohort (N = 79).
We further stratified the patients with MCI into stable MCI (sMCI, N = 37), i.e.
most recent clinical status remains MCI with at least 36 months follow up, and
progressors (pMCI, N = 19), i.e. individuals whose most recent known clinical
status is AD dementia, with progression from MCI to AD dementia occurring
within 37 months. The HPS model selected a subset of 10 MCI subjects. Using
the longitudinal follow-up clinical data provided by ADNI2, we found that 9 out
8
Table 1: Supervised classification of MCI progression to AD dementia using the ADNI
database. Progression time was establish if the the subject progresses to AD status in the
next 36 months. Significant improvement of our method compared to each paper for the ad-
justed accuracy and precision (adjusted for a pMCI ratio of 34% comparable to our sample)
and specificity are shown with ∗ for p < 0.05 and ∗∗ for p < 0.001) and conversely signifi-
cant decrease in sensitivity of our method compared to each paper. Adjusted accuracy (Acc),
adjusted precision (Prec), specificity (Spec), sensitivity (Sens)
N Acc Prec Spec Sens
Article sMCI/pMCI adjusted
Dansereau et al. (This paper)37/19 80% 90% 97% 47%
Mathotaarachchi et al. (2017) 230/43 82% 74% 87%* 71%*
Korolev et al. (2016) 120/139 79% 65%* 76%**83%*
Moradi et al. (2015) 100/164 78% 63%* 74%**87%**
Eskildsen et al. (2013) 134/149 67%**52%** 68%**66%
Wee et al. (2013) 111/89 77% 68%* 84%**64%
Gaser et al. (2013) 62/133 80% 70%* 84%**71%*
Davatzikos et al. (2011) 170/69 79% 63%* 71%**95%**
Koikkalainen et al. (2011) 215/154 73%* 58%* 71%**77%*
Misra et al. (2009) 76/27 67%**51%** 60%**80%*
of 10 of these subjects were pMCI (precision of 90%, specificity of 97%, sensi-
tivity of 47%), compared to 34% pMCI in the whole MCI sample (p < 0.001),
Figure 5A. Within the HPS subgroup, the time to progression from baseline
to the first evaluation of AD dementia appeared uniformly distributed from 5
to 37 months, with 50% subjects progressing after 24 months (Figure 5C). In
addition, 100% of the MCI participants flagged as HPS were tested positive
for beta amyloid deposition with AV45 testing, compared to a 69% rate in the
whole MCI sample (p < 0.05), Figure 5A. The rate of ApoE4 carriers in the
HPS subsample was 78%, compared to 55% in the whole MCI group (p > 0.05),
Figure 5A. A similar observation could be made regarding the rate of male of
70% in the HPS subsample and 52% in the whole MCI group (p > 0.05). Finally
the average age in the HPS group was of 74 years ±7 and 71 years ±7 for the
whole MCI group (p > 0.05).
3. Discussion
The main goal of this work was to develop an imaging-based AD diagno-
sis and prognosis with high precision and specificity. The proposed HPS ap-
proach did reach excellent performance in these respects, with 100% precision
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Figure 5: Statistics on the MCI showing the signature. Panel A shows the percentage of MCI
who progress to AD, the percentage of subjects positive for beta amyloid deposits using the
AV45 marker and the percentage of carriers of one or two copies of the ApoE4 allele for the
entire MCI cohort. Panel B shows the same statistics for the selection of the base classifier
while Panel C displays statistics for subjects flagged as HPS. Panel D shows the clinical status
of each HPS subject over time from the baseline scan.
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and specificity when distinguishing patients with AD dementia from CN partic-
ipants and 90% precision, 98% specificity when predicting which MCI patients
would progress to dementia, up to three years before onset (see Table S2). These
results represent a sizable and significant improvement in precision and speci-
ficity over previous models on this task, see Table 1. The high specificity of the
HPS model came at the cost of a limited sensitivity, which is significantly less
than most recent published models, see Table 1. Previous models from the liter-
ature could likely be tuned to work in a regime of high specificity and precision
as well as the one proposed here. Actually, the base SVM classifier can achieve
a precision close to our two-stage model, when adjusting the decision threshold
(see Supplementary Material S2B for ROC curves). The main contribution of
this work was to demonstrate using proper cross-validation that a model can be
trained in this regime of high precision and specificity. The second contribution
was to show that the subset of patients at high risk of progression can be iden-
tified using a limited set of easily interpretable “subtypes”, and that was made
possible by the two-stage model. The results of (Beach et al., 2012) suggest
that only about half of patients diagnosed with AD dementia have clear AD
brain markers post-mortem. The HPS was identified in 38% of patients with
AD dementia and 47% of progressor MCI patients, which is consistent with the
idea that the HPS model is picking on a typical brain presentation of AD that
is already present at the prodromal stage of the disease.
The anatomical features selected by the method were in line with recent
subtyping works, e.g. (Hwang et al., 2015), showing predominant atrophy in
the temporal lobe, as well as the temporo-parietal juncture, in particular. The
functional maps were more difficult to interpret, and seemed to capture some
noise pattern. They still made a significant improvement in the performance of
the HPS model. Because of the regularization in the logistic regression used to
build the HPS model, features coming from different modalities did compete to
be selected in the model. If redundant features existed, the ones with largest
predictive power were selected by the classifier. This may explain why the
selected functional subtypes did not involve the regions showing atrophy in the
structural subtypes. We hypothesized that the HPS inferred from the AD vs
CN prediction would also be useful to predict if a subject at the prodromal
stage (MCI) would progress to dementia. Our results did validate this logic,
but alternative strategies may be investigated in the future, e.g. training a
model directly on the progressor vs stable MCI.
A limitation of the present study was a moderate sample size, with N = 56
patients suffering from MCI. While the ADNI database is large, resting-state
fMRI has only been added to the protocol in the later stages of the study,
ADNI GO and ADNI2. In addition, fMRI was only acquired on a third of the
participants, even after it was added to the protocol. Because of the early role
of synaptic dysfunction in AD, and the potential ability of fMRI to capture
such dysfunction, we wanted to build an anatomo-functional diagnostic tool.
But this choice did limit the sample size of our study since the selected subjects
needed to have imaging data of the two modalities and pass their respective
quality control assessment. Even with a larger sample size, another limitation
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of the ADNI dataset is that it does not reflect the diversity of cases observed
in real-life clinical practice. Participants were in particular screened to exclude
vascular dysfunction, which is a common comorbidity in AD (Gorelick et al.,
2011). Resources with more inclusive enrollment criteria will help to better
assess the generalizability of a biomarker-based AD diagnosis.
The most direct application of the HPS model is its use for population enrich-
ment in pharmaceutical clinical trials on AD (Woo et al., 2017; Mathotaarachchi
et al., 2017). By recruiting patients who would normally progress to AD demen-
tia, such an enrichment would increase the effect size of the drug while reducing
the sample size needed to demonstrate efficacy and therefore would also reduce
the cost of the trial. The HPS brain signature is not shared among all the AD
dementia population (making it a subtype), but is common enough to represent
a substantial portion of participants of interest (about a third of AD demen-
tia subjects and half of MCI progressors). An alternative enrichment strategy,
more geared towards generalizability, would be to only exclude subjects that
will very likely not progress to AD dementia. The HPS method thus brings us
closer to precision medicine by proposing a middle ground between traditional
clinical cohorts and an entirely individual medicine.
In this manuscript, we focused exclusively on two MRI modalities. Our ra-
tionale was that MRI is non-invasive and already widely used in patient care
of elderly populations. Beta amyloid and tau PET imaging, by contrast, are
more expensive and less available, while lumbar punctures are invasive. Never-
theless, as shown in our results the combination of multimodal factors may help
to improve precision, specificity and sensitivity. Since the sensitivity of each
modality to abnormality may vary across the disease stages it may be benefi-
cial to combine them to obtain complementary information. It will therefore
be important in the future to see if a combination of PET imaging, blood tests
targeting specific markers, cognitive scores, genetic factors, lifestyle factors, or
others can help create stronger or multiple HPS that would in effect increase
the sensitivity of the model at earlier stages of the of Alzheimer’s disease.
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5. Materials and methods
Dataset
All functional and structural data were obtained from the Alzheimer’s Dis-
ease Neuroimaging Initiative 2 (ADNI2) sample, a longitudinal standardized
acquisition including three populations: cognitively normal subjects (N = 49,
46% male, 74±7 years of age), patients with mild cognitive impairment (N = 56,
51% male, 72±7.5 years of age) and patients with dementia due to AD (N = 24,
46% male, 72 ± 7 years of age). All participants gave their written informed
consent to participate in the ADNI2 study, which was approved by the local
ethics committee of participating institutions across North America. The con-
sent form included data sharing with collaborators as well as secondary analysis.
The present secondary analysis of the ADNI2 sample was approved by the local
ethics committee at CRIUGM, University of Montreal, QC, Canada. All resting-
state fMRI and structural scans were acquired on 3T Philips scanners with 8
channel head coils. We performed analyses on the first usable scan (typically
the baseline scan) from ADNI2.
The acquisition parameters were as follows: structural scan 170 slices, voxel
size 1x1x1.2 mm3, matrix size 256x256, FOV 256 mm2, TR 6.8 s, TE 3.09
ms, FA 9 degrees. A functional scan of 7 min, 48 slices, voxel size 3.3x3.3x3.3
mm3, matrix size 64x64, FOV 212 mm2, TR 3 s, TE 30 ms, FA 80 degrees,
No. volumes 140. For detailed information on the acquisition, see www.adni-
info.org.
1www.fnih.org
2https://computecanada.org/
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Extraction of functional features
Each fMRI dataset was corrected for slice timing; a rigid-body motion was
then estimated for each time frame, both within and between runs, as well as
between one fMRI run and the T1 scan for each subject (Collins et al., 1994).
The T1 scan was itself non-linearly co-registered to the Montreal Neurological
Institute (MNI) ICBM152 stereotaxic symmetric template (Fonov et al., 2011),
using the CIVET pipeline (Ad-Dab’bagh et al., 2006a). The rigid-body, fMRI-
to-T1 and T1-to-stereotaxic transformations were all combined to resample the
fMRI in MNI space at a 3 mm isotropic resolution. To minimize artifacts due
to excessive motion, all time frames showing a frame displacement, as defined
in Power et al. (2012), greater than 0.5 mm were removed. An average residual
frame displacement was also estimated after scrubbing for further group anal-
yses. A minimum of 50 unscrubbed volumes per run was required for further
analysis (13 subjects were rejected). The following nuisance covariates were
regressed out from fMRI time series: slow time drifts (basis of discrete cosines
with a 0.01 Hz highpass cut-off), average signals in conservative masks of the
white matter and the lateral ventricles as well as the first principal compo-
nents (accounting for 95% variance) of the six rigid-body motion parameters
and their squares (Giove et al., 2009; Lund et al., 2006). The fMRI volumes
were finally spatially smoothed with a 6 mm isotropic Gaussian blurring ker-
nel. Datasets were preprocessed and analyzed using the NeuroImaging Analysis
Kit - NIAK - version 0.12.17 (http://niak.simexp-lab.org), under CentOS with
Octave (http://gnu.octave.org) version 3.6.1 and the MINC toolkit (http://bic-
mni.github.io/) version 0.3.18. Preprocessing of MRI data was executed in par-
allel on the Guillimin supercomputer (http://www.calculquebec.ca/en/resources/compute-
servers/guillimin), using the pipeline system for Octave and Matlab - PSOM
(Bellec et al., 2012). Seed-based fMRI connectivity maps were obtained using
a functional brain template of 20 networks covering the entire brain (Urchs
et al., 2017). The Pearson’s correlation between the average time series of each
network and every voxel of the brain was computed to derive one functional
connectivity map per network.
Extraction of structural features
Native individual T1-weighted MRI scans were corrected for non-uniformity
artifacts with the N3 algorithm (Sled et al., 1998). The corrected volumes were
then masked for brain tissues (Smith, 2002) and registered into stereotaxic space
(Collins et al., 1994). The registered images were segmented into gray matter
(GM), white matter (WM), cerebrospinal fluid (CSF) and background using a
neural net classifier (Tohka et al., 2004). The WM and GM surfaces were ex-
tracted using the Constrained Laplacian-based Automated Segmentation with
Proximities algorithm (Kim et al., 2005; MacDonald et al., 2000) and were re-
sampled to a stereotaxic surface template to provide vertex based measures and
lobar segmentation (Lyttelton et al., 2007). Cortical thickness was measured in
native space using the linked distance between the two surfaces across 81,924
vertices (Im et al., 2008). Surface-based cortical thickness, as well as regional
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Figure 6: Panel A shows the feature extraction method called subtypes weights, Panel B frame-
work workflow: stage 1 shows the hit probability computation based on random sub-sampling
and stage 2 shows the training of dedicated classifier for each high-confidence signature. Panel
C shows the nested cross-validation scheme used in this method.
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volume measures, were obtained using the structural MRI images processed us-
ing the CIVET 1.1.12 pipeline for each hemisphere as described in Ad-Dab’bagh
et al. (2006b). The AAL template was applied on each hemisphere (40 regions
per hemisphere) to extract the regional volumetric measures. The processing
pipeline was executed on the Canadian Brain Imaging Network (CBRAIN) plat-
form, a network of five imaging centers and eight High-Performance Computers
for collaborative sharing and distributed processing of large MRI databases
(Frisoni et al., 2011).
Multimodal imaging subtypes
We extracted subtypes that characterize the interindividual variability within
the sample comprising CN and AD participants (at the time of scanning), inde-
pendently for each type of measure (functional maps, cortical thickness maps,
and volumetric maps). In order to reduce the impact of some factors of no
interest that may influence the clustering procedure, we regressed out the age,
sex, and average post-scrubbing frame displacement from individual map, using
a mass univariate linear regression model at each voxel. For each type of brain
measure, we derived a spatial Pearson’s correlation coefficient between all pairs
of individual maps. This defined a subject x subject similarity matrix (of size
73 x 73), which was entered into a Ward hierarchical clustering procedure, as
implemented in SciPy version 0.18.1 (Jones et al., 2001–; Walt et al., 2011). We
selected three subgroups for each type of measure, based on a visual examina-
tion of the similarity matrix. For each type of measure, the average map of each
subgroup defined a subtype. For each individual, we computed the spatial cor-
relation of their map with each subtype. The resulting weight measures formed
a matrix of size (number of subjects) x (number of subtypes), which was used
as the feature space for all predictive models throughout the rest of this work.
Prediction of AD
The baseline prediction accuracy was obtained by training a SVM model with
a linear kernel, as implemented in Scikit-learn Pedregosa et al. (2011) version
0.18. A tenfold cross-validation loop was used to estimate the performance of
the trained model, including the entire subtyping procedure and regression of
confounds. Classes were balanced inversely proportional to class frequencies
in the input data for the training. A nested cross-validation loop was used
(stratified shuffle split (50 splits, 20% test size)) for the grid search of the hyper-
parameter C (grid was 10−2 to 101 with 15 steps). Note that the C parameter
controlled how many misclassified examples the model will tolerate by adjusting
the margin size. The model was evaluated using fMRI features only, sMRI
features only, and the combination of fMRI and sMRI features.
Identifying easy cases
We randomly selected subsamples of the dataset (retaining 80% of partic-
ipants in each subsample) to replicate the SVM training 100 times. For each
80% subsample, a separate SVM model was trained to predict the clinical labels
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(CN or AD), see Figure 6B. Note that the optimal C parameter was estimated
once using the whole available sample, as described above, and used across all
subsamples. This was done to avoid creating major uncontrolled algorithmic
variations. The linear discriminating weights of the SVM were still optimized
independently for each subsample. Predictions of clinical labels were then made
on the remaining 20% of subjects, that were not used for training. For a given
individual, the hit probability was calculated as the frequency of correct clinical
classification across all available SVM replications where the test set included
that individual. Easy cases were defined as individuals with 100% hit probabil-
ity.
Predicting easy cases
We trained a logistic regression classifier Fan et al. (2008a) to predict the
AD easy cases. The logistic regression was trained using a L1 regularization on
the coefficients, see Figure 6B. Class weight was balanced inversely proportional
to class frequencies in the input data. A stratified shuffle split (100 splits, 20%
test size) was used to estimate the performance of the model for the grid search
of the hyper-parameter C (grid was 10−0.2 to 101 with 15 equal steps). In this
case, the C parameter controlled the sparseness of the weights.
Cross-validation
A nested cross-validation was performed for accuracy estimation and pa-
rameters optimization. The outer loop used to estimate the generalizability of
the framework was a ten-fold cross-validation scheme. Each training fold in-
cluded the full multi-stage process of subtype extraction, SVM prediction of
clinical labels, identification of HPS and prediction of HPS with logistic regres-
sion. Sensitivity (true positive rate, TP), specificity (true negative rate, TN)
and precision (TP/(TP + (1− TN))) of the diagnosis were estimated across all
test folds, in the AD vs CN prediction. Cross-validation nested inside the outer
loop was used to search for the optimal hyper-parameters, Figure 6C.
Prediction of progression to dementia
The HPS was obtained by applying the subtyping and easy cases recognition
to the whole CN and AD sample, and considering all subtypes associated with
non-zero weights by the sparse logistic regression model in Figure 6C stage 2.
The logistic regression trained on AD vs CN was used to identify MCI patients
who have a HPS of AD dementia. The imaging sample for this experiment
included the baseline structural and functional scans of all patients with MCI
in the ADNI2 cohort, with at least 36 months of follow-up (N = 56). We further
stratified the patients with MCI into stable MCI (sMCI, N = 37)), i.e. latest
clinical status is MCI, and progressors (pMCI, N = 19), i.e. individuals whose
most recent known clinical status is AD dementia, with progression from MCI
to AD dementia occurring within 36 months. Note that no AV45 imaging data
or genetic data, nor any data from the MCI cohort, were used to build the HPS
model.
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Statistical test of differences in model performance
We generated a confidence interval on the performance (i.e. precision, speci-
ficity and sensitivity) of a given model using a Monte-Carlo simulation. Tak-
ing the observed sensitivity and specificity, and using similar sample size to
our experiment, we replicated the number of true and false positive detection
100000 times using independent Bernoulli variables, and derived replications
of precision, specificity and sensitivity. By comparing these replications to the
sensitivity, specificity and precision observed in other models, we estimated a
p-value for differences in model performance (Phipson and Smyth, 2010). A
p-value smaller than 0.05 was interpreted as evidence of a significant difference
in performance, and 0.001 as a strong evidence. This approach was first used in
Figure 3 to contrast the performance of the HPS model to the baseline (SVM)
model, both for AD vs CN and MCI progressor vs stable, as well as contrasting
the performance of multimodal (fMRI+sMRI) model vs models using only fMRI
or sMRI features. The same approach was used to contrast our proposed model
for MCI progressor vs stable with results from the literature, in Table 1. Note
that, based on our hypotheses regarding the behaviour of the HPS model, the
tests were one-sided for increase in specificity and precision, and one-sided for
decrease in sensitivity.
Statistical test of enrichment
The HPS model was used to select a subset of the MCI population. We tested
statistically if this subgroup was enriched for (1) progression to dementia; (2)
AV45+, and; (3) ApoE4+. We implemented for this purpose a Monte-Carlo
simulation, where we selected 100000 random subgroups out of the original
MCI sample. By comparing the proportion of progressors (respectively AV45+
and ApoE4+) in these null replications to the actual observed values in the
HPS subgroup, we estimated a p-value (Phipson and Smyth, 2010) (one sided
for increase). A p-value smaller than 0.05 was interpreted as evidence of a
significant enrichment, and 0.001 as a strong evidence.
Public code and data
The code used in this experiment is available on a GitHub repository at the
following URL3. An IPython Notebook is also provided with all of the figure
generation scripts. Scikit-learn Pedregosa et al. (2011) version 0.18 was used
for most of the machine learning algorithms and Nilearn Abraham et al. (2014)
version 0.2.6 for visualization purposes.
ADNI dataset
Data used in the preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI
3https://github.com/cdansereau/HPS
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was launched in 2003 as a public-private partnership, led by Principal Investiga-
tor Michael W. Weiner, MD. The primary goal of ADNI has been to test whether
serial magnetic resonance imaging (MRI), positron emission tomography (PET),
other biological markers, and clinical and neuropsychological assessment can be
combined to measure the progression of mild cognitive impairment (MCI) and
early Alzheimer’s disease (AD).
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Figure S1: Hit-probability distribution obtained from replicating the SVM training 100 times
from 80% of the training set.
Supplementary Material – A brain signature highly predictive of future
progression to Alzheimer’s dementia
Table S2: Performance of the models. Prec: precision, Spec: specificity, Sens: sensitivity and
N: number of selected subjects.
Modality AlgoContrast Prec (%)Spec (%)Sens (%)N
fMRI BaseCN/AD 38.10 46.94 66.67 42
HPS 60 95.92 12.5 5
sMRI Base 66.67 83.67 66.67 24
HPS 87.50 97.96 29.17 8
fMRI+sMRIBase 69.57 85.71 66.67 23
HPS 100 100 37.50 9
fMRI+sMRIBasesMCI/pMCI73.33 89.19 57.89 15
HPS 90 97.3 47.37 10
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Figure S2: Panel A show the ROC curve of the base classifier and HPS classifier for the
simulation example of Figure 1 and on the right the precision vs specificity curves. Panel B
show the same curves for the MCI progressors task.
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